The point at which doctors assess biomarkers of mesothelioma patients’ response to a combination of chemotherapy and immunotherapy is crucial to obtaining a clear picture of…
Read More
The more mesothelioma tumor cells that express the mesothelin protein, the longer a patient is likely to live, according to a study. That finding is…
Read More
The U.S. Food and Drug Administration has granted Humanitarian Use Device (HUD) status to Novocure‘s Tumor Treating Fields (TTFields) for treating pleural mesothelioma. The designation…
Read More
A Phase 3 British clinical trial will test whether the immune checkpoint inhibitor Opdivo (nivolumab) can help mesothelioma patients whose disease relapsed after platinum-based chemotherapy.…
Read More
Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda…
Read More
Yondelis (trabectedin) stabilized a form of advanced mesothelioma that had progressed after earlier chemotherapy, according to a Phase 2 clinical trial in Italy. Researchers will…
Read More
Bristol-Myers Squibb is recruiting 600 participants into a global Phase 3 clinical trial investigating a combination of two immune checkpoint inhibitors — Opdivo (nivolumab) and…
Read More
Soluble mesothelin, a cell surface glycoprotein predominant in several types of cancer, is an independent prognostic marker and a new potential therapeutic target for patients…
Read More
Workers who are exposed to asbestos early in their career are at higher risk of developing pleural mesothelioma (PM) than those who were exposed later…
Read More
LONDON, ENGLAND - In recent years, England has seen an increase in illegal tobacco products, many of which are tainted with asbestos. This increase is…
Read More
